Muraglitazar, a dual (α/γ) PPAR activator: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes
- 31 August 2005
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 27 (8) , 1181-1195
- https://doi.org/10.1016/j.clinthera.2005.08.005
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Lipids and Glucose in Type 2 DiabetesDiabetes Care, 2004
- Use and Abuse of HOMA ModelingDiabetes Care, 2004
- Standards of Medical Care in DiabetesDiabetes Care, 2004
- Dyslipidemia Management in Adults With DiabetesDiabetes Care, 2004
- Thiazolidinedione Use, Fluid Retention, and Congestive Heart FailureCirculation, 2003
- PPARγANDGLUCOSEHOMEOSTASISAnnual Review of Nutrition, 2002
- Effect of Experimental Elevation of Free Fatty Acids on Insulin Secretion and Insulin Sensitivity in Healthy Carriers of the Pro12Ala Polymorphism of the Peroxisome Proliferator–Activated Receptor-γ2 GeneDiabetes, 2001
- Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.Diabetes Care, 2000
- Gemfibrozil treatment of endogenous hypertriglyceridemia: effect on insulin-mediated glucose disposal and plasma insulin concentrationsJournal of Clinical Endocrinology & Metabolism, 1996
- Pathogenesis of NIDDM: A Balanced OverviewDiabetes Care, 1992